Townsend & Associates Inc Sells 30,623 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Townsend & Associates Inc reduced its stake in Edwards Lifesciences Corporation by 14.3% in the second quarter, selling 30,623 shares and bringing its total holdings to 184,176 shares, valued at approximately $14.7 million.
• Edwards Lifesciences reported earnings of $0.67 per share, exceeding analyst expectations, with quarterly revenue increasing by 11.9% year-over-year to $1.53 billion.
• Analyst sentiment is largely positive, with William Blair upgrading the stock to a "strong-buy" and an average price target of $87.06 reflecting a "Moderate Buy" rating among research analysts.

Townsend & Associates Inc trimmed its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 14.3% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 184,176 shares of the medical research company's stock after selling 30,623 shares during the quarter. Edwards Lifesciences accounts for about 1.5% of Townsend & Associates Inc's holdings, making the stock its 26th biggest holding. Townsend & Associates Inc's holdings in Edwards Lifesciences were worth $14,734,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Quantbot Technologies LP bought a new stake in Edwards Lifesciences during the 1st quarter valued at $26,000. SouthState Corp bought a new stake in Edwards Lifesciences during the 1st quarter valued at $27,000. Rosenberg Matthew Hamilton bought a new stake in Edwards Lifesciences during the 2nd quarter valued at $28,000. Tradewinds Capital Management LLC raised its holdings in Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after buying an additional 205 shares during the last quarter. Finally, Rossby Financial LCC bought a new stake in Edwards Lifesciences during the 1st quarter valued at $29,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Up 2.5%

Shares of Edwards Lifesciences stock opened at $74.50 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The company has a 50-day moving average of $77.54 and a 200 day moving average of $76.21. The firm has a market cap of $43.74 billion, a price-to-earnings ratio of 10.72, a PEG ratio of 3.58 and a beta of 1.05. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the business earned $0.70 EPS. Edwards Lifesciences's quarterly revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on EW. William Blair upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Stifel Nicolaus set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a "buy" rating in a research report on Monday, September 22nd. Daiwa America raised shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. Evercore ISI set a $88.00 price objective on shares of Edwards Lifesciences and gave the company an "outperform" rating in a research report on Tuesday, October 7th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $87.06.

Insider Activity

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company's stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.34% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.